ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

3:00PM-3:50PM: Abstract Number: 0970

Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes

RA – Etiology & Pathogenesis (0970–0974)

3:00PM-3:50PM: Abstract Number: 0974

Role of NR4A Nuclear Receptor Family in RA Synovial Ectopic Lymphoid Neogenesis Revealed by Single Cell Profiling

RA – Etiology & Pathogenesis (0970–0974)

3:00PM-3:50PM: Abstract Number: 0971

Single-cell Profiling of Synovial Stromal Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis

RA – Etiology & Pathogenesis (0970–0974)

3:00PM-3:50PM: Abstract Number: 0979

The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW

SLE – Animal Models (0975–0979)

3:00PM-3:50PM: Abstract Number: 0988

Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis

SLE – Treatment (0985–0989)

3:00PM-3:50PM: Abstract Number: 0989

Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial

SLE – Treatment (0985–0989)

5:00PM-5:50PM: Abstract Number: 0967

Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model

RA – Animal Models (0965–0969)

5:00PM-5:50PM: Abstract Number: 0968

Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice

RA – Animal Models (0965–0969)

5:00PM-5:50PM: Abstract Number: 0966

Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3

RA – Animal Models (0965–0969)

5:00PM-5:50PM: Abstract Number: 0954

Dual-energy CT Predicts Mortality in Gout Patients: A 3-year Follow-up Cohort Study

Metabolic & Crystal Arthropathies (0950–0954)

5:00PM-5:50PM: Abstract Number: 0982

Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

5:00PM-5:50PM: Abstract Number: 0980

Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time-trends, Healthcare Utilization and In-Hospital Mortality

SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

5:00PM-5:50PM: Abstract Number: 0969

Investigating Murine Joint-Draining Lymphatics: Lineage Tracing and Single Cell RNA Sequencing Reveal Evidence That Popliteal Lymphatic Muscle Cells and Their Progenitors Represent Distinct Cell Types Divergent from Striated and Vascular Muscle Cells

RA – Animal Models (0965–0969)

5:00PM-5:50PM: Abstract Number: 0953

Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout

Metabolic & Crystal Arthropathies (0950–0954)

5:00PM-5:50PM: Abstract Number: 0981

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017

SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].